Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares
(Thomson Reuters ONE) -
DUBLIN, Ireland, April 8, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapy
programs, announced today that it priced an underwritten public offering of
3,300,000 of its ordinary shares at a price to the public of $37.00 per ordinary
share, before the underwriting discount. All of the ordinary shares in the
offering were sold by Prothena. In addition, Prothena has granted the
underwriters a 30-day option to purchase up to an additional 495,000 of its
ordinary shares.
Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the
offering are expected to be $114.2 million, after deducting the underwriting
discount and estimated offering expenses, but excluding any exercise of the
underwriters' option to purchase additional ordinary shares. The offering is
expected to close on April 13, 2015, subject to customary closing conditions.
Credit Suisse, RBC Capital Markets and UBS Investment Bank are acting as joint
book-running managers, and Oppenheimer & Co., Wedbush PacGrow, Ladenburg
Thalmann and LifeSci Capital are acting as co-managers for the offering.
The ordinary shares of Prothena described above were offered only by means of a
prospectus supplement and base prospectus forming part of an effective shelf
registration statement filed with the Securities and Exchange Commission. Copies
of the prospectus for this offering may be obtained, when available, by
contacting Credit Suisse Securities (USA) LLC, One Madison Avenue, New York, NY
10010; Tel: 1-800-221-1037; Attention: Credit Suisse Prospectus Department,
email: newyork.prospectus(at)credit-suisse.com; RBC Capital Markets, LLC, 200 Vesey
Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; Tel:
(877) 822-4089; email: equityprospectus(at)rbccm.com; or UBS Securities LLC, 1285
Avenue of the Americas, New York, New York 10019; Attention Prospectus
Department; Tel: (888) 827-7275.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or other jurisdiction.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused
on the discovery, development and commercialization of novel protein
immunotherapy programs for the potential treatment of diseases that involve
amyloid or cell adhesion. The Company is developing antibody-based product
candidates that target a number of potential indications including AL
amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies
(PRX002) and psoriasis and other inflammatory diseases (PRX003).
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate
to, among other things, the timing and size of the proposed offering, the
conditions affecting the capital markets, general economic, industry, or
political conditions, and the satisfaction of customary closing conditions
related to the proposed offering. These statements are based on estimates,
projections and assumptions that may prove not to be accurate, and actual
results could differ materially from those anticipated due to known and unknown
risks, uncertainties and other factors, including but not limited to the risks,
uncertainties and other factors described in the "Risk Factors" sections of
Prothena's Annual Report on Form 10-K filed with the Securities and Exchange
Commission (SEC) on March 13, 2015 and in the prospectus supplement related to
the offering filed with the SEC. Prothena undertakes no obligation to update
publicly any forward-looking statements contained in this press release as a
result of new information, future events or changes in Prothena's expectations.
CONTACT: Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Angela Bitting
925-202-6211, angela.bitting(at)prothena.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
[HUG#1909311]
Unternehmensinformation / Kurzprofil:
Datum: 08.04.2015 - 12:00 Uhr
Sprache: Deutsch
News-ID 384303
Anzahl Zeichen: 5172
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 112 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
